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Background: Post-transplant recurrent nephritis is the third common complication that leads to graft loss, which
affects the long-term graft survival of kidney transplant patients. Immunoglobulin A nephropathy (IgAN) is the most
common for recurrent nephritis, with a recurrence rate of 13–53%. In this study, 12 patients diagnosed with recurrent
IgAN were divided into two groups, one which underwent tonsillectomy and another which did not, to analyze the
effect of treating IgAN recurrent with or without tonsillectomy.
Methods: Urinary findings, estimated GFR (eGFR), and histopathological alteration (Banff and Oxford classifications)
were examined for >5 years after kidney transplantation.
Results: We found that tonsillectomy protected graft function and prevented pathological alterations. The levels of
urinary proteins increased in the no tonsillectomy group, whereas no difference was observed in the severity of
hematuria between two groups. eGFR declined and mesangial hypercellularity score increased in the no tonsillectomy
group.
Conclusions: Tonsillectomy not only results in a favorable clinical outcome but also protects against the histological
damage caused by recurrent IgAN after kidney transplantation.
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The recurrence rate of IgAN in renal graft is 13–53%
among transplant recipients with IgAN, which affects
long-term graft survival [1, 2]. In recent trials of im-
munosuppression therapy, mycophenolate mofetil was
expected to suppress IgAN after transplantation;
however, it failed to enhance graft survival [3]. In
another study of 532 transplant recipients by Esther
et al., graft loss due to IgAN recurrence occurred in
as many as 9.7% patients at 10 years. Among these,
IgAN accounted for 22% of the total cases of graft
loss, IgAN recurrence was the third major cause of
graft loss after chronic rejection and death with a
functioning graft [4]. Establishing a treatment for
recurrent nephritis, particularly recurrent IgAN, is* Correspondence: kensakai@med.toho-u.ac.jp
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et al. first described IgAN in 1968 [5]; it is now the
most frequent form of chronic glomerulonephritis in
Japan. In another study, Xie et al. compared patients
with primary IgAN that did or did not undergo ton-
sillectomy, and renal survival rates for the two groups
at 240 months were 89.6 and 63.7%, respectively; this
difference was statistically significant [6]. Tonsillec-
tomy monotherapy or steroid pulse therapy following
tonsillectomy is commonly used to treat primary
IgAN in Japan [6–9]. This therapy achieves particu-
larly beneficial effects in the early stages of IgAN.
Protocol graft biopsy can reveal important findings
regarding the onset and extension of IgAN, which
might explain why tonsillectomy has particularly fa-
vorable effects on early stage recurrent IgAN. To our
knowledge, few reports have assessed the natural pro-
gression of recurrent IgAN using protocol graft
biopsies.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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tomy for the treatment of IgAN recurrence after kidney
transplantation.
Methods
Between 1984 and 2008, kidney transplantation was per-
formed on 520 patients at our department. Among these
recipients, 76 (14.6%) were diagnosed with primary IgAN
that was confirmed pathologically. Among these, 23
(30.3%) had recurrent IgAN in the kidney graft. After ex-
cluding individuals who we were unable to follow-up for
5 years or more, 12 patients were included in the final
analysis. All 12 patients received immunosuppressive ther-
apy including tacrolimus, cyclosporine, azathioprine, my-
cophenolate mofetil (MMF), and methylprednisolone
during the study period. IgAN recurrence was defined as
follows:
1. The confirmation of primary IgAN using a native
kidney biopsy.
2. The new appearance of urinary findings (proteinuria
and/or hematuria)
3. New-onset histological IgA deposition without
previous IgAN deposition at 1-h biopsy.
Tonsillectomy was offered to all 12 patients as a treat-
ment option, and it was only performed on patients who
provided consent. After given the informed consent, five
patients (tonsillectomy group) underwent tonsillectomy,
whereas the remaining seven patients (no tonsillectomy
group) did not. Protocol biopsies were routinely performed
at 1 h, 3 months, 12 months, 36 months, 60 months, and
84 months after kidney transplantation. One nephrologist
and one or two pathologists evaluated the pathological
findings using the Banff classification 2007 [10] and the
Oxford classification [11, 12]. Informed consent was
obtained from all patients regarding the use of their patho-
logical specimens in this study before each graft biopsy.
The degree of urinary findings, histopathological alter-
ations, the decline slope of 1/Cr, and estimated glomeru-
lar filtration (eGFR) were analyzed retrospectively in the
two patient groups. Microhematuria was defined as five
or more erythrocytes per high-power microscopy field
(×400) in urinary sediment, according to the Japanese Uro-
logical Association guidelines. Proteinuria was evaluated
using the protein/creatinine ratio (g/gCr) in a urine sample
obtained in the morning at the outpatient clinic. eGFR was
calculated using serum creatinine levels on the day or the
day before the renal biopsy. Clinical data are expressed as
mean ± standard deviations (SDs). Statistical comparisons
between the two groups were performed using Wilcoxon
rank sum test, and individual pairs of specimens were ana-
lyzed using matched-pair t tests. P < 0.05 was considered
to denote statistical significance in all tests.This study was approved by the Ethics Committee of
Toho University Omori Medical Center, Tokyo, Japan
(approval number: 26–60), and was performed in adher-
ence with the Declaration of Helsinki. Informed consent
was obtained from all patients.
Results
In the tonsillectomy group, two patients were male and
three were female, and the mean age was 33.7 ± 9.7 years at
kidney transplantation. The mean period from transplant-
ation to IgAN recurrence was 37.4 ± 25.7 months, and the
median time between IgAN recurrence and tonsillectomy
was 3.1(1.4–28.9) months. The mean follow-up period after
kidney transplantation was 146.8 ± 30.1 months. At the
time of the diagnosis of IgAN recurrence, the mean serum
creatinine (SCr) levels were 1.15 ± 0.28 mg/dl (eGFR was
47.7 ± 14.6 ml/min/1.73 m2). Three of the five patients
(60%) had hematuria, and the mean proteinuria was
0.33 ± 0.52 g/gCr. All patients were administered antihyper-
tensive agents such as angiotensin-converting enzyme in-
hibitors (ACE-I) or angiotensin receptor blockers (ARB)
after IgAN recurrence was confirmed. The no tonsillectomy
group included six males and one female with mean age of
36.6 ± 8.6 years. The mean period from transplant to IgAN
recurrence was 31.8 ± 19.3 months, and the mean follow-
up period was 193.6 ± 105.1 months. The mean SCr and
eGFR at the time of diagnosis of IgAN recurrence was 1.29
± 0.17 mg/dl and 39.1 ± 5.8 ml/min/1.73 m2, respectively.
Four of seven patients (57%) had hematuria, and the mean
proteinuria was 0.07 ± 0.19 g/gCr. ACE-I or ARB therapy
was initiated after IgAN recurrence was confirmed in all
but one patient. All patients were re-evaluated for IgAN re-
currence or not by repetitive protocol biopsy (Table 1).
We showed a recurrence rate in each protocol graft bi-
opsy within all cases: 1 h, 0%; 3 months, 8.3%; 12 months,
25%; 3 years, 41.7%; 5 years, 25%; 7 year, 0%. Among 3 years
after transplantation, 66% of recurrence was noted.
The therapeutic response was measured by assessing
hematuria and proteinuria in each group. The tonsillec-
tomy group exhibited more proteinuria than did the no
tonsillectomy group at recurrence. However, no signifi-
cant differences were observed in the degree of protein-
uria between groups (0.33 ± 0.52 vs. 0.07 ± 0.19 g/gCr,
respectively; p = 0.33). In the no tonsillectomy group, the
mean proteinuria at recurrence was 0.07 ± 0.19 g/gCr,
which increased significantly to 0.97 ± 1.09 g/gCr at
60 months after recurrence (p = 0.043). However, no
significant change was observed in proteinuria in the
tonsillectomy group (0.33 ± 0.52 vs. 0.40 ± 0.53 g/gCr,
p = 0.87) during the same observation period (Fig. 1a, b).
No significant differences were observed in the degree of
hematuria between groups.
In terms of the histological damage caused by IgAN in
the tonsillectomy group, no significant differences were
Table 1 Patient characteristics
Tonsillectomy (n = 5) No tonsillectomy (n = 7) p
Recipient gender (M/F) 2/3 6/1 0.10
Recipient age at transplantation (mean ± SD) 33.7 ± 9.7 36.6 ± 8.6 0.75
Donor age at transplantation (mean ± SD) 57.7 ± 15.5 53.1 ± 17.1 1.00
Duration of pre-transplant dialysis (months) 41.3 ± 42.1 9.6 ± 3.6 0.10
Living/deceased 5/0 6/1 1.00
ABO compatible/incompatible 3/2 7/0 0.15
Immunosuppressant use (CsA/FK) 3/2 6/1 0.52
SCr at recurrence (mg/dl) 1.15 ± 0.28 1.29 ± 0.17 0.33
eGFR at recurrence (ml/min) 47.7 ± 14.6 39.1 ± 5.8 0.33
Urinary findings at recurrence
Hematuria 3/5 (60%) 4/7 (57%) 1.00
Proteinuria (g/g·Cr) 0.33 ± 0.52 0.07 ± 0.19 0.39
Use of RASI 5/5 (100%) 6/7 (85.7%) 1.00
Period between transplant and IgAN recurrence (months) 37.4 ± 25.7 31.8 ± 19.3 0.94
Median time between IgAN recurrence and tonsillectomy (months) 3.1(1.4 − 28.9) – –
Time between IgAN recurrence and the next protocol biopsy (months) 57.4 ± 10.1 61.4 ± 8.5 0.76
Follow-up period (months) 146.8 ± 30.1 193.6 ± 105.1 0.75
Fig. 1 a Changes in urinary protein excretion in patients with or without tonsillectomy. *p < 0.05, urinary protein excretion at 60 months vs. at
recurrence in patients with no tonsillectomy. b Changes in urinary protein by individuals with or without tonsillectomy
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Table 2 Changes in renal pathological findings in patients with
or without tonsillectomy according to the Banff classification





Banff classification t 0.60 ± 0.89 0.20 ± 0.45 0.48
i 0.60 ± 0.89 0.20 ± 0.45 0.48
v 0 0.20 ± 0.45 0.37
g 0.20 ± 0.45 0.20 ± 0.45 1.00
ci 0 0.60 ± 0.55 0.07
ct 0.40 ± 0.55 0.80 ± 0.45 0.37
mm 0.40 ± 0.55 0.80 ± 0.45 0.37
cg 0 0 –
cv 0.40 ± 0.55 0.40 ± 0.89 1.00
ah 0.20 ± 0.45 0.60 ± 0.89 0.18
ptc 0.20 ± 0.45 0.60 ± 0.89 0.48
Scl (%) 6.20 ± 6.46 18.06 ± 22.02 0.19
Oxford classification M 0.24 ± 0.21 0.32 ± 0.29 0.59
S 0.40 ± 0.55 0.40 ± 0.55 1.00
E 0.20 ± 0.45 0 0.37
T 0 0.20 ± 0.45 0.37
No tonsillectomy group
Banff classification t 0.14 ± 0.38 0.14 ± 0.38 1.00
i 0.14 ± 0.38 0 0.36
v 0 0 –
g 0 0.14 ± 0.38 0.36
ci 0.14 ± 0.38 0.29 ± 0.49 0.60
ct 0.43 ± 0.53 0.71 ± 0.49 0.17
mm 0.14 ± 0.38 2.14 ± 0.69 0.002
cg 0 0.29 ± 0.49 0.17
cv 0.43 ± 0.53 0.71 ± 0.76 0.17
ah 0.29 ± 0.38 0.71 ± 0.49 0.20
ptc 0.14 ± 0.38 0.14 ± 0.38 1.00
Scl (%) 6.43 ± 11.43 14.5 ± 13.45 0.25
Oxford classification M 0.20 ± 0.36 0.69 ± 0.37 0.003
S 0 0.57 ± 0.54 0.03
E 0 0.14 ± 0.38 0.36
T 0.24 ± 0.21 0.14 ± 0.38 0.25
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after tonsillectomy. However, in the no tonsillectomy
group, the mesangial matrix score (mm) in the Banff clas-
sification 2007 increased from 0.14 ± 0.38 to 2.14 ± 0.69
(p = 0.002), the mesangial hypercellularity score (MS) in
the Oxford classification increased from 0.20 ± 0.36 to
0.69 ± 0.37 (p = 0.003), and the segmental glomeruloscreo-
sis score (SS) in the Oxford classification increased from 0
to 0.57 ± 0.54 (p = 0.03) (Table 2). Pathological rejection,
except for borderline changes, was not observed during
the study period.
Figure 2 shows the change in eGFR between groups.
The decreases in eGFR before and 60 months after trans-
plantation were as follows: tonsillectomy group, 47.7 ± 14.6
to 34.8 ± 12.2 ml/min/1.73 m2 (p = 0.11); no tonsillectomy
group, 39.1 ± 5.8 to 30.4 ± 10.2 ml/min/1.73 m2 (p = 0.03).
In terms of the change in 1/Cr between groups, the de-
creases in 1/Cr before and 60 months after transplantation
were as follows: tonsillectomy group, 0.91 ± 0.21 to 0.73 ±
0.26 mg/dl (p = 0.14); no tonsillectomy group, 0.79 ± 0.11
to 0.65 ± 0.22 ml/min/1.73 m2 (p = 0.03). Although eGFR
and 1/Cr reduced in both groups, the decline was only sig-
nificant in the no tonsillectomy group. No patients in the
tonsillectomy group experienced renal graft loss, while
three (42.3%) patients lost their graft in the no tonsillec-
tomy group (Fig. 3). Among these, the mean graft survival
was 11.3 ± 6.8 years, and the reason for graft loss was
followed, two patients for IgAN recurrence, one patient for
interstitial fibrosis and tubular atrophy (IF/TA).
Discussion
We found that tonsillectomy is an effective treatment
for IgAN recurrence after kidney transplantation both
clinically and pathologically. Hotta et al. reported that
tonsillectomy and steroid pulse therapy had a significant
effect in patients with primary IgAN. In addition, pa-
tients with early to mid-stage primary IgAN with rela-
tively preserved renal function were more likely to
respond satisfactorily [13]. In the current study, the ton-
sillectomy group exhibited no significant differences in
the degree of proteinuria and eGFR. Graft loss did not
occur during the observation period, and there were no
remarkable changes in mesangial hypercellularity score
(MS in the Oxford classification) or matrix expansion
(mm score in the Banff classification 2007).
Kennoki et al. conducted a retrospective study of 28
transplant recipients with IgAN recurrence and persist-
ent proteinuria. Of the 16 and 12 patients with or with-
out tonsillectomy during a mean follow-up period of
60 months, proteinuria decreased significantly in all ton-
sillectomized patients but did not in no tonsillectomy
patients. No significant differences were observed in the
degree of hematuria and eGFR between the groups [14].
In other study, Ushigome et al. analyzed four transplantrecipients with IgAN recurrence who underwent tonsil-
lectomy. The urinary findings were improved in all
patients after tonsillectomy, including a histologically se-
vere case, for a mean period of 13.5 months [15]. Fur-
thermore, Koshino et al. reported date from seven
transplant recipients with IgAN recurrence who under-
went tonsillectomy. Both of urinary findings and SCr
levels improved in the mild-grade recurrent IgAN cases
Fig. 2 a Changes in renal function (1/Cr) in patients with or without tonsillectomy. *p < 0.05, 1/Cr at 60 months vs. at recurrence in patients with
no tonsillectomy. b Changes in estimated glomerular filtration rate (eGFR) in patients with or without tonsillectomy. *p<0.05, eGFR at 60 months
vs. at recurrence in patients with no tonsillectomy
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48.4 months [16].
In the current study, patients with tonsillectomy group
exhibited improved urinary findings, whereas proteinuria
increased significantly in the no tonsillectomy group. Con-
sistent with previous studies, tonsillectomy treatment
reduced proteinuria. We hypothesize that tonsillectomy
alone protects graft function and pathology. In the tonsil-
lectomy group, the slope of eGFR seemed to be greater,
but SD was higher in tonsillectomy than no tonsillectomy
group, higher SD might result in no statistical different
during 60 months observation. We therefore tried to show
graft function by other parameter instead of eGFR (Fig.
2a), the slope of 1/Cr was similar as the slope of eGFR.
Although the decline of eGFR (from 47.7 to 34.8ml/min)
was 27.0% during 60 months (less than 30%) in the tonsil-
lectomy group (Fig. 2b), the most important factor for
IgAN progression depends on the amount of proteinuria
at the same kidney function [17].
Ohya and Shigematsu et al. showed that the efficacy of
tonsillectomy in IgAN in native kidney [18]. Mean age
(34.6 years) and levels of serum creatinine (0.9 mg/dl) and
proteinuria (0.87 g/dl) were similar to our studyFig. 3 Kaplan-Meier analysis of graft survival in patients with or
without tonsillectomypopulation. They concluded that tonsillectomy resulted in
lower relapse after achieving remission compared to ster-
oid therapy alone. In order to reveal the effect of tonsillec-
tomy alone, our results as well as other reports [18] made
possible this hypothesis. The mechanism of tonsillectomy
is an antigenic stimulation of immune system by the ton-
sillar mucosa via the mucosa-bone marrow axis [19].
Histological evidence is required to confirm that ton-
sillectomy exhibits a graft-protecting effect. In the
current study, there was no change in mesangial cell
proliferation in the tonsillectomy group. In contrast, the
mm, MS, and SS scores significantly increased in the no
tonsillectomy group. This suggests that tonsillectomy
improves mesangial cell proliferation and matrix expan-
sion. Hotta et al. reported that both of urinary findings
and graft pathology were improved in 15 transplant re-
cipients with IgAN recurrence who underwent tonsillec-
tomy [20]. Although their results were consistent with
those of the current study, they were unable to confirm
IgAN as a primary disease in those recipients.
When considering the effects of tonsillectomy, it is ne-
cessary to compare a tonsillectomy group to no tonsil-
lectomy group. It is also important to confirm any
changes pathologically using protocol graft biopsies.
However, several previous studies [14–16, 20] did not
perform long-term evaluations using protocol graft biop-
sies. We can also evaluate rejection according to the
Banff classification and aggravation of the IgAN process
for long-term observation about 10 years. The Banff
classification is a useful tool for standardizing to evaluate
rejection, but it is not designed to evaluate the recur-
rence of nephritis. On the other hand, the Oxford classi-
fication was announced in 2009 by a working group of
the International IgAN Network and Association of
International Kidney Pathology. It analyzes the reprodu-
cibility of lesions in IgAN by every pathologist, and it
then can be confirmed as the responsible lesion for the
prognosis of IgAN. This classification also takes into
consideration the mesangial cells proliferation, which is
an important reason why this classification system was
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ally categorized with mild histological findings; therefore,
lesions such as cellular crescents, fibrocellular crescents,
and intraluminal lesions are usually not considered.
Therefore, we utilized the Oxford classification system
with the Banff classification to determine IgAN recur-
rence in the current study. Even if just mild lesion seen
at protocal biopsy, tonsillectomy resulted in favorable
outcome based on repetitive biopsies in our study.
The effectiveness of tonsillectomy and steroid pulse
combined-therapy, for improving mesangial cell prolifera-
tion and fibrosis, has been reported previously [13, 22].
However, there is concern that the additional steroid pulse
therapy might lead to over-immunosuppression. There-
fore, many physicians hesitate steroid pulse therapy in
patients with recurrent IgAN after transplantation.
Although, the postoperative use of immunosuppressive
agents might suppress the development of IgAN, the
addition of steroid pulse therapy is doubted for taking a
side effect into account. Immunosuppressive therapy
might not successfully prevent from IgAN recurrence
even in this era after kidney transplantation [23]; there-
fore, we evaluated the efficacy of tonsillectomy alone in
the current study.
Study limitations
This study has three limitations: First, the number of cases
was insufficient in both groups. In order to make a diag-
nosis of recurrent IgAN, both pre- and post-transplant
renal biopsy diagnosis is required. Unfortunately, there
were few patients who diagnosed IgAN as primary disease.
We extensively recruited patients since 1984 because of
above reason. Second, more patients with proteinuria
were included in the tonsillectomy group; therefore, there
is a selection bias in this retrospective study. Third, most
of patients introduce our hospital to transplant purpose;
we could not take information about IgAN activity in
detail.
Conclusions
This study demonstrated that tonsillectomy protected
clinical and pathological alteration in patients with IgAN
recurrence after kidney transplantation. However, a large
sample size and more long-term observation are neces-
sary to determine the effectiveness of tonsillectomy in
case of IgAN recurrence after kidney transplantation.
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